ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΤΜΗΜΑ ΧΗΜΕΙΑΣ ΕΡΓΑΣΤΗΡΙΟ ΒΙΟΧΗΜΕΙΑΣ
H αθηπωμαηική πλάκα ηος διαβηηικού αζθενή
Αλέξανδπορ Δ. Τζελέπηρ Καθηγητής Βιοχημείας-Κλινικής Χημείας
Creager MA, et al. Circulation 2003;108:1527
Hyperglycemia increases flux through the polyol pathway
Brownlee M. Diabetes. 2005; 54:1615
Increased production of AGE precursors
Brownlee M. Diabetes. 2005; 54:1615
Pathways of AGEs formation
Jakus V, et al. Physiol. Res. 53: 131-142, 2004
Structures of some most important AGEs
Pentosidine, Argpyrimidine, Carboxymethyllysine (CML), Carboxyethyllysine (CEL), Pyrraline, Glyoxal-lysine dimer (GOLD), Methylglyoxal-lysine dimer (MOLD), Crosslines
Jakus V, et al. Physiol. Res. 53: 131-142, 2004
RAGE-dependent perpetuated NF-κB activation
Bierhaus A, et al. J Mol Med (2005) 83: 876–886
Consequences of increased AGE production
Brownlee M. Diabetes. 2005; 54:1615
Consequences of hyperglycemia-induced activation of PKC
Brownlee M. Diabetes. 2005; 54:1615
Hyperglycemia increases flux through the hexosamine pathway
Brownlee M. Diabetes. 2005; 54:1615
Oxidative phosphorylation, superoxide production, and scavenging pathways in Mitochondria
Madamanchi NR, et al. Circ. Res. 2007;100;460-473
Hyperglycemia and Insulin resistance-induced increased mitochondrial superoxide production activates atherogenic signaling pathways
Madamanchi NR, et al. Circ. Res. 2007;100;460-473
Possible mechanisms by which glucose and AGEs can affect atherogenesis in diabetes
Mazzone Th, et al. Lancet 2008; 371: 1800–09
Macrophage biology in type-2 diabetes mellitus and atherosclerosis
Mazzone Th, et al. Lancet 2008; 371: 1800–09
Hyperglycemia and endothelium-derived vasoactive substances
Creager MA, et al. Circulation 2003;108:1527-1532
eNOS and PGI2 synthase are two critical antiatherogenic enzymes
Brownlee M. Diabetes. 2005; 54:1615
Mechanisms of platelet activation associated with diabetes mellitus
Ferroni P, et al. J Thromb Haemost 2004; 2: 1282–91
Effects of altered glycemic control on platelet function
Ferroni P, et al. J Thromb Haemost 2004; 2: 1282–91
Platelet function and plasma coagulation factors are altered in diabetes, favoring platelet aggregation and a propensity for thrombosis
Creager MA, et al. Circulation 2003;108:1527-1532
Metabolic basis of the atherogenic lipoprotein phenotype in type 2 diabetes
Chapman MJ. Diabetes Vasc Dis Res 2007;4 (Suppl):S5-S8
Σχημαηιζμός πλούζιων ζε TG ζωμαηιδίων VLDL1
Ρόλος ηης HL ζηο μεηαβολιζμό ηων apoB-λιποπρωηεϊνών
VLDL1
Metabolic basis of the atherogenic lipoprotein phenotype in type 2 diabetes
Chapman MJ. Diabetes Vasc Dis Res 2007;4 (Suppl):S5-S8
Lipoprotein changes in type 2 diabetes mellitus
Mazzone Th, et al. Lancet 2008; 371: 1800–09
Formation of Gly-ox-LDL and Gly-ox-HDL
Hyperglycemia and Oxidative stress induce dysfunctional HDL
Kontush A, et al. Pharmacol Rev 58:342–374, 2006
Diabetic dyslipidemia and the vessel wall
Mazzone Th, et al. Lancet 2008; 371: 1800–09
Inflammation in diabetic coronary arteries
Type 2-DM
Type 1-DM
Non-Diabetic
Burke AP, et al. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271
Expression of S100A12/ENRAGE (a RAGE-binding protein) in human coronary lesions from sudden coronary death victims
Diabetes (A–E)
No Diabetes (F–J)
Burke AP, et al. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271
Combined effect of hyperlipidemia and diabetes on atherosclerotic plaque components
Burke AP, et al. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271
Plaque Characteristics in Type I and II Diabetic Subjects vs Nondiabetic Subjects
Burke AP, et al. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271
Antiatherosclerosis Therapy in Diabetes
Beckman JA, et al. JAMA. 2002;287:2570-2581